David Furfaro

Dr. David Furfaro

orcid

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2018 in Annals of the American Thoracic Society
Verified
Journal Article
Closed access
DFDavid Furfaro
David Furfaro
RSR. Scott Stephens
R. Scott Stephens
MSMichael B. Streiff
Michael B. Streiff
RBRoy Brower
Roy Brower
Intermediate-risk pulmonary embolism is common and carries a risk of progression to hemodynamic collapse and death. Catheter-directed thrombolysis is an increasingly used treatment option, based largely on the assumptions that it is more efficacious than anticoagulation alone and safer than systemic thrombolysis. In this review, we critically analyze the published data regarding catheter-directed thrombolysis for the treatment of intermediate-risk pulmonary embolism. Catheter-directed thrombolysis reduces right heart strain and lowers pulmonary artery pressures more quickly than anticoagulation alone. The mortality for patients with intermediate-risk pulmonary embolism treated with catheter-directed thrombolysis is low, between 0% and 4%. However, similarly low mortality is seen with anticoagulation alone. Catheter-directed thrombolysis appears to be safer than systemic thrombolysis, and procedural complications are uncommon. Bleeding risk appears to be slightly higher than with anticoagulation alone. Randomized, controlled trials are needed to compare the efficacy and safety of catheter-directed thrombolysis versus anticoagulation for intermediate-risk pulmonary embolism. There is no evidence that catheter-directed thrombolysis decreases the incidence of chronic thromboembolic pulmonary hypertension. There is no evidence from clinical studies that ultrasound-assisted thrombolysis is more effective or safer than standard catheter-directed thrombolysis.

1 December 2021 in The Journal of Heart and Lung Transplantation
Verified
Journal Article
Closed access
DFDavid Furfaro
David Furfaro
ERErika B. Rosenzweig
Erika B. Rosenzweig
LSLori Shah
Lori Shah
HRHilary Robbins
Hilary Robbins
MAMichaela Anderson
Michaela Anderson
LBLuke Benvenuto
Luke Benvenuto

27 February 2024 in Chest
Verified
Journal Article
Closed access
JRJonah Rubin
Jonah Rubin
AWAlison S. Witkin
Alison S. Witkin
JCJerome C. Crowley
Jerome C. Crowley
EMEriberto Michel
Eriberto Michel
DFDavid Furfaro
David Furfaro
EFEddy Fan
Eddy Fan

17 April 2024 in CHEST Critical Care
Verified
Journal Article
Open access
FAFatimah A. Alkhunaizi
Fatimah A. Alkhunaizi
NSNikolhaus Smith
Nikolhaus Smith
SBSamuel B. Brusca
Samuel B. Brusca
DFDavid Furfaro
David Furfaro
Cardiogenic shock (CS) is a heterogenous syndrome broadly characterized by inadequate cardiac output leading to tissue hypoperfusion and multisystem organ dysfunction that carries an ongoing high mortality burden. The management of CS has advanced rapidly, especially with the incorporation of temporary mechanical circulatory support (tMCS) devices. A thorough understanding of how to approach a patient with CS and to select appropriate monitoring and treatment paradigms is essential in modern ICUs. Timely characterization of CS severity and hemodynamics is necessary to optimize outcomes, and this may be performed best by multidisciplinary shock-focused teams. In this article, we provide a review of CS aimed to inform both the cardiology-trained and non-cardiology-trained intensivist provider. We briefly describe the causes, pathophysiologic features, diagnosis, and severity staging of CS, focusing on gathering key information that is necessary for making management decisions. We go on to provide a more detailed review of CS management principles and practical applications, with a focus on tMCS. Medical management focuses on appropriate medication therapy to optimize perfusion-by enhancing contractility and minimizing afterload-and to facilitate decongestion. For more severe CS, or for patients with decompensating hemodynamic status despite medical therapy, initiation of the appropriate tMCS increasingly is common. We discuss the most common devices currently used for patients with CS-phenotyping patients as having left ventricular failure, right ventricular failure, or biventricular failure-and highlight key available data and particular points of consideration that inform tMCS device selection. Finally, we highlight core components of sedation and respiratory failure management for patients with CS.

30 October 2024 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
JFJohn H. Fountain
John H. Fountain
TPTyler Peck
Tyler Peck
DFDavid Furfaro
David Furfaro
Among survivors of acute pulmonary embolism (PE), roughly half report persistent dyspnea, impaired functional status, and decreased quality of life. Post-pulmonary embolism syndrome (PPES) is a broad condition which has been increasingly recognized in recent years and may be due to post-pulmonary embolism functional impairment, chronic thromboembolic disease, or the most severe long-term complication of PE, chronic thromboembolic pulmonary hypertension. Despite guideline recommendations for appropriate follow-up for post-pulmonary embolism patients, PPES remains underrecognized and diagnostic testing underutilized. Patients with symptoms suggestive of PPES at follow-up should undergo a transthoracic echocardiogram to screen for the presence of pulmonary hypertension; additional testing, such as a ventilation/perfusion scan, right heart catheterization, and cardiopulmonary exercise testing may be indicated. The pathophysiology of post-pulmonary embolism syndrome is complex and heterogeneous. In chronic thromboembolic pulmonary hypertension, the pathophysiology reflects persistent pulmonary arterial thrombi and a progressive small vessel vasculopathy. In patients with chronic thromboembolic disease or chronic thromboembolic pulmonary hypertension, medical therapy, balloon pulmonary angioplasty, or pulmonary thromboendarterectomy should be considered, and in cases of chronic thromboembolic pulmonary hypertension, pulmonary thromboendarterectomy significantly improves mortality. In all causes of post-pulmonary embolism syndrome, rehabilitation is a safe treatment option that may improve quality of life.

8 April 2024 in Chest
Verified
Journal Article
Closed access
DFDavid Furfaro
David Furfaro
LCLeo Anthony Celi
Leo Anthony Celi
RSRichard M. Schwartzstein
Richard M. Schwartzstein